RATIONALE: Repeated antigen-driven proliferations cause CD28 on T cells to down-regulate. We hypothesized that alloantigen-induced proliferations could cause CD28 down-regulation in lung transplant recipients. OBJECTIVES: To ascertain if CD28 down-regulation on CD4 T cells associated with manifestations of allograft dysfunction in lung transplant recipients. METHODS: Peripheral blood CD4 T cells from 65 recipients were analyzed by flow cytometry, cytokine multiplex and proliferative assays, and correlated with clinical events. MEASUREMENTS AND MAIN RESULTS: Findings that CD28 was present on less than 90% of total CD4 T cells were predominantly seen among the recipients with bronchiolitis obliterans syndrome (specificity = 88%). Perforin and granzyme B were produced by >50% of the CD4(+)CD28(null) cells, but less than 6% of autologous CD4(+)CD28(+) cells (P < 0.006). CD4(+)CD28(null) cells also had increased productions of proinflammatory cytokines, but less frequently expressed regulatory T-cell marker FoxP3 (2.1 +/- 1.3%), compared with autologous CD4(+)CD28(+) (9.5 +/- 1.4; P = 0.01). Cyclosporine A (100 ng/ml) inhibited proliferation of CD4(+)CD28(null) cells by 33 +/- 11% versus 68 +/- 12% inhibition of CD4(+)CD28(+) (P = 0.025). FEV(1) fell 6 months later (0.35 +/- 0.04 L) in recipients with CD4(+)CD28(+)/CD4(total) less than 90% (CD28% Low) compared with 0.08 +/- 0.08 L among CD4(+)CD28(+)/CD4(total) (CD28% High) greater than 90% (CD28% High) recipients (P = 0.013). Two-year freedom from death or retransplantation in CD28% Low recipients was 32 +/- 10% versus 78 +/- 6% among the CD28% High subjects (P < 0.0001). CONCLUSIONS: CD28 down-regulation on CD4 cells is associated with bronchiolitis obliterans syndrome and poor outcomes in lung transplantation recipients. CD4(+)CD28(null) cells have unusual, potentially pathogenic characteristics, and could be important in the progression of allograft dysfunction. These findings may illuminate a novel paradigm of transplantation immunopathogenesis, and suggest that CD28 measurements could identify recipients at risk for clinical deteriorations.
RATIONALE: Repeated antigen-driven proliferations cause CD28 on T cells to down-regulate. We hypothesized that alloantigen-induced proliferations could cause CD28 down-regulation in lung transplant recipients. OBJECTIVES: To ascertain if CD28 down-regulation on CD4 T cells associated with manifestations of allograft dysfunction in lung transplant recipients. METHODS: Peripheral blood CD4 T cells from 65 recipients were analyzed by flow cytometry, cytokine multiplex and proliferative assays, and correlated with clinical events. MEASUREMENTS AND MAIN RESULTS: Findings that CD28 was present on less than 90% of total CD4 T cells were predominantly seen among the recipients with bronchiolitis obliterans syndrome (specificity = 88%). Perforin and granzyme B were produced by >50% of the CD4(+)CD28(null) cells, but less than 6% of autologous CD4(+)CD28(+) cells (P < 0.006). CD4(+)CD28(null) cells also had increased productions of proinflammatory cytokines, but less frequently expressed regulatory T-cell marker FoxP3 (2.1 +/- 1.3%), compared with autologous CD4(+)CD28(+) (9.5 +/- 1.4; P = 0.01). Cyclosporine A (100 ng/ml) inhibited proliferation of CD4(+)CD28(null) cells by 33 +/- 11% versus 68 +/- 12% inhibition of CD4(+)CD28(+) (P = 0.025). FEV(1) fell 6 months later (0.35 +/- 0.04 L) in recipients with CD4(+)CD28(+)/CD4(total) less than 90% (CD28% Low) compared with 0.08 +/- 0.08 L among CD4(+)CD28(+)/CD4(total) (CD28% High) greater than 90% (CD28% High) recipients (P = 0.013). Two-year freedom from death or retransplantation in CD28% Low recipients was 32 +/- 10% versus 78 +/- 6% among the CD28% High subjects (P < 0.0001). CONCLUSIONS:CD28 down-regulation on CD4 cells is associated with bronchiolitis obliterans syndrome and poor outcomes in lung transplantation recipients. CD4(+)CD28(null) cells have unusual, potentially pathogenic characteristics, and could be important in the progression of allograft dysfunction. These findings may illuminate a novel paradigm of transplantation immunopathogenesis, and suggest that CD28 measurements could identify recipients at risk for clinical deteriorations.
Authors: Marc Estenne; Janet R Maurer; Annette Boehler; James J Egan; Adaani Frost; Marshall Hertz; George B Mallory; Gregory I Snell; Samuel Yousem Journal: J Heart Lung Transplant Date: 2002-03 Impact factor: 10.247
Authors: Andras Komocsi; Peter Lamprecht; Elena Csernok; Antje Mueller; Konstanze Holl-Ulrich; Ulrike Seitzer; Frank Moosig; Armin Schnabel; Wolfgang Ludwig Gross Journal: Am J Pathol Date: 2002-05 Impact factor: 4.307
Authors: Pio Conti; Duraisamy Kempuraj; Kristiana Kandere; Mario Di Gioacchino; Renato C Barbacane; Maria L Castellani; Mario Felaco; William Boucher; Richard Letourneau; Theoharis C Theoharides Journal: Immunol Lett Date: 2003-04-03 Impact factor: 3.685
Authors: Steven R Duncan; Colm Leonard; James Theodore; Mark Lega; Reda E Girgis; Glenn D Rosen; Argyrios N Theofilopoulos Journal: Am J Respir Crit Care Med Date: 2002-05-15 Impact factor: 21.405
Authors: Shiraz A Daud; Roger D Yusen; Bryan F Meyers; Murali M Chakinala; Michael J Walter; Aviva A Aloush; G Alexander Patterson; Elbert P Trulock; Ramsey R Hachem Journal: Am J Respir Crit Care Med Date: 2006-12-07 Impact factor: 21.405
Authors: O Traitanon; A Gorbachev; J J Bechtel; K S Keslar; W M Baldwin; E D Poggio; R L Fairchild Journal: Am J Transplant Date: 2014-05-19 Impact factor: 8.086
Authors: Jianmin Xue; Xuehai Zhu; M Patricia George; Michael M Myerburg; Michael W Stoner; Joseph W Pilewski; Steven R Duncan Journal: Am J Pathol Date: 2011-06-12 Impact factor: 4.307
Authors: A Mohammed; O Ulukpo; E C Lawrence; F Fernandez; A Pickens; A A Gal; S D Force; K C Easley; C P Larsen; A D Kirk; D C Neujahr Journal: Transplant Proc Date: 2011-12 Impact factor: 1.066
Authors: Syed R Gilani; Louis J Vuga; Kathleen O Lindell; Kevin F Gibson; Jianmin Xue; Naftali Kaminski; Vincent G Valentine; Emily K Lindsay; M Patricia George; Chad Steele; Steven R Duncan Journal: PLoS One Date: 2010-01-29 Impact factor: 3.240
Authors: Jason W Chien; Steven Duncan; Kirsten M Williams; Steven Z Pavletic Journal: Biol Blood Marrow Transplant Date: 2009-11-05 Impact factor: 5.742
Authors: Jianmin Xue; Bernadette R Gochuico; Ahmad Samer Alawad; Carol A Feghali-Bostwick; Imre Noth; Steven D Nathan; Glenn D Rosen; Ivan O Rosas; Sanja Dacic; Iclal Ocak; Carl R Fuhrman; Karen T Cuenco; Mary A Smith; Susan S Jacobs; Adriana Zeevi; Penelope A Morel; Joseph M Pilewski; Vincent G Valentine; Kevin F Gibson; Naftali Kaminski; Frank C Sciurba; Yingze Zhang; Steven R Duncan Journal: PLoS One Date: 2011-02-23 Impact factor: 3.240
Authors: Christina Duftner; Christian Dejaco; Paul Hengster; Klaudija Bijuklic; Michael Joannidis; Raimund Margreiter; Michael Schirmer Journal: PLoS One Date: 2012-03-30 Impact factor: 3.240